Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A
Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A
Repligen Corporation announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world’s approved monoclonal antibodies. The patent, which will remain …
Read more on News-Medical-Net
Related posts:
- How does protein synthesis process effect the distribution of hypocretin protein in narcolepsy people?
- Sleepy Disabled Lady Receives Awards for Her Writing
- The Sleep Disorder Market Worth $2.03bn is Set for Reform as Market Leaders Lose Their Patent Protection
- Browse News
- B Street Theatre’s ‘Conductor’ delivers a vital chapter of freedom